MetaCap

Connect Biopharma (CNTB) vs Elicio Therapeutics (ELTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Connect Biopharma (CNTB) has outperformed Elicio Therapeutics (ELTX) over the past year, losing 80.6% versus a loss of 82.8%. Over five years, CNTB leads with a -86.9% price change compared with -96.1% for ELTX. Elicio Therapeutics is the larger company by market cap ($41.0 million vs $38.0 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CNTB-80.59%ELTX-82.84%
+84%-4%-91%
Nov 21, 20251 yearNov 20, 2026
CNTB-88.48%ELTX-96.46%
+5%-48%-101%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CNTB versus ELTX key metrics
MetricCNTBELTX
Share price$0.59$1.45
Market cap$38.05M$41.05M
1-day change-6.08%-3.33%
YTD return-79.08%-81.78%
1-year return-80.59%-82.84%
5-year return-86.89%-96.13%
EPS (TTM)$-1.14$-1.81
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$64.00K—
Revenue growth (YoY)-99.75%—
Net income (latest FY)$-55.48M$-39.57M
Operating margin-90740.63%—
Net margin-86687.50%—
52-week high$3.82$16.00
52-week low$0.55$1.25
Distance from 52-week high-84.55%-90.94%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+896.61%+842.76%
Average volume3.98M324.71K
Shares outstanding64.49M28.31M
Employees6433
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Connect Biopharma

CNTB stock →

Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD).

Health Care · Biotechnology: Pharmaceutical Preparations · 64 employees

About Elicio Therapeutics

ELTX stock →

Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations.

Health Care · Biotechnology: Pharmaceutical Preparations · 33 employees

CNTB vs ELTX FAQ

Which is bigger, Connect Biopharma or Elicio Therapeutics?

Elicio Therapeutics (ELTX) is larger, with a market capitalization of $41.05M compared with $38.05M for Connect Biopharma (CNTB).

Which stock has performed better over the past year, CNTB or ELTX?

CNTB returned -80.59% over the past 12 months, compared with -82.84% for ELTX (price return, excluding dividends). Past performance does not predict future results.

Are Connect Biopharma and Elicio Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons